BioRad Laboratories (BIO)
(Delayed Data from NYSE)
$325.29 USD
-3.07 (-0.93%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $325.23 -0.06 (-0.02%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Price, Consensus and EPS Surprise
BIO 325.29 -3.07(-0.93%)
Will BIO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BIO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BIO
Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Guidance Lowered
Bio-Rad Laboratories (BIO) Surpasses Q2 Earnings Estimates
BIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
What's in Store for These 4 MedTech Stocks in Q2 Earnings?
All You Need to Know About Bio-Rad (BIO) Rating Upgrade to Buy
Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?
Other News for BIO
OncoCyte announces successful GraftAssure beta launch
What's Driving Globus Medical Inc's Surprising 37% Stock Rally?
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX), Denali Therapeutics (DNLI) and Bio-Rad Laboratories (BIO)
Hold Rating Maintained for Bio-Rad Laboratories Amid Mixed Performance and Market Headwinds
Bio-Rad price target raised by $50 at Citi, here's why